Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2811 + durvalumab maintenance in first-line ES-SCLC
2024-511887-10-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of defosbarasertib and durvalumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Primary endpoint: Maintenance participants alive and progression free at 12 months (APF12). Planned start Jul 2024; status: authorised.
02
Drugs
defosbarasertibdurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-511887-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511887-10-00.